Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia

Clinical and Vaccine Immunology

Volumn 15, Issue 10, 2008, Pages 1536-1540

  Ochi, Hiroyuki ^a,b   Kondo, Kazunari ^a,b   Matsumoto, Koji ^b   Oki, Akinori ^b   Yasugi, Toshiharu ^c   Furuta, Reiko ^d   Hirai, Yasuo ^e   Yoshikawa, Hiroyuki ^b   Kanda, Tadahito ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d CANCER INSTITUTE   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS DNA; VIRUS ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CANCER GRADING; DNA DETERMINATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; JAPAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRION; VIRUS CULTURE; BLOOD; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; SERODIAGNOSIS; VIROLOGY; VIRUS INFECTION;

ADULT; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEUTRALIZATION TESTS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 55449100910     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00197-08     Document Type: Article

References (23)

1. Buck, C. B., D. V. Pastrana, D. R. Lowy, and J. T. Schiller. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757.
2. Buck, C. B., N. Cheng, C. D. Thompson, D. R. Lowy, A. C. Steven, J. T. Schiller, and B. L. Trus. 2008. Arrangement of L2 within the papillomavirus capsid. J. Virol. 82:5190-5197.
3. Chen, X. S., R. L. Garcea, I. Goldberg, G. Casini, and S. C. Harrison. 2000. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 5:557-567.
4. de Villiers, E. M., C. Fauquet, T. R. Broker, H. U. Bernard, and H. zur Hausen. 2004. Classification of papillomaviruses. Virology 324:17-27.
5. Doorbar, J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 110:525-541.
6. Giannini, S. L., E. Hanon, P. Moris, M. Van Mechelen, S. Morel, F. Dessy, M. A. Fourneau, B. Colau, J. Suzich, G. Losonksy, M. T. Martin, G. Dubin, and M. A. Wettendorf. 2006. Enhanced humoral and memory B cellular using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24:5937-5949.
7. Giroglou, T., M. Sapp, C. Lane, C. Fligge, N. D. Christensen, R. E. Streeck, and R. C. Rose. 2001. Immunological analyses of human papillomavirus capsids. Vaccine 19:1783-1793.
8. Harper, D. M., E. L. Franco, C. M. Wheeler, A. B. Moscicki, B. Romanowski, C. M. Roteli-Martins, D. Jenkins, A. Schuind, S. A. Costa Clemens, G. Dubin, et al. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367:1247-1255.
9. Kirnbauer, R., F. Booy, N. Cheng, D. R. Lowy, and J. T. Schiller. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89:12180-12184.
10. Kondo, K., Y. Ishii, H. Ochi, T. Matsumoto, H. Yoshikawa, and T. Kanda. 2007. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358:266-272.
11. Kondo, K., H. Ochi, T. Matsumoto, H. Yoshikawa, and T. Kanda. 2008. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J. Med. Virol. 80:841-846.
12. Koutsky, L. A., K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. B. Alvarez, L. M. Chiacchierini, and K. U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
13. Maehama, T. 2005. Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterin cervix. Infect. Dis. Obstet. Gynecol. 13:77-80.
14. Mbulawa, Z. Z., A. L. Williamson, D. Stewart, J. A. Passmore, L. Denny, B. Allan, and D. J. Marais. 2008. Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease. J. Gen. Virol. 89:910-914.
15. Muñoz, N., F. X. Bosch, X. Castellsague, M. Diaz, S. Sanjose, D. Hammouda, K. V. Shah, and C. J. L. M. Meijer. 2004. Against which human papillomavirus types shall we vaccinate and screen? Int. J. Cancer 111:278-285.
16. Pastrana, D. V., C. B. Buck, Y. Y. Pang, C. D. Thompson, P. E. Castle, D. C. FitzGerald, S. Kruger Kjaer, D. R. Lowy, and J. T. Schiller. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
17. Pisani, P., F. Bray, and M. Parkin. 2002. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 97:72-81.
18. Schiffman, M., P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907.
19. Smith, J. F., M. Brownlow, M. Brown, R. Kowalski, M. T. Esser, W. Ruiz, E. Barr, D. R. Brown, and J. T. Bryan. 2007. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum. Vaccin. 3:109-115.
20. Steele, J., S. Collins, K. Wen, G. Ryan, C. Constandinou-Williams, and C. B. J. Woodman. 2008. Measurement of the humoral immune response following an incident HPV16 or HPV18 infection in young women by a pseudovirion-based neutralizing antibody assay. Clin. Vaccine Immunol. 15: 1387-1390.
21. Villa, L. L., R. L. Costa, C. A. Petta, R. P. Andrade, K. A. Alut, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, F. F. Skjeldestad, S. E. Olsson, M. Steinwall, D. R. Brown, R. J. Kurman, B. M. Ronnett, M. H. Stoler, A. Frenczy, D. M. Harper, G. M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F. J. Taddeo, K. U. Jansen, M. T. Esser, H. L. Sings, A. J. Saah, and E. Barr. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.
22. Winer, R. L., Q. Feng, J. P. Hughes, M. Yu, N. B. Kiviat, S. O'Reilly, and L. A. Koutsky. 2007. Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex. Transm. Dis. 34:371-377.
23. Yoshikawa, H., T. Kawana, K. Kitagawa, M. Mizuno, H. Yoshikura, and A. Iwamoto. 1991. Detection and typing of multiple genital papillomaviruses by DNA amplification with consensus primers. Jpn. J. Cancer Res. 82:524-531.